AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial

AstraZeneca Plc AZN released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease or death in a late-stage study.

The drug, a cocktail of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50% in non-hospitalized patients who have had symptoms for seven days or less, meeting the primary goal of the study.

Having enrolled more than 800 non-hospitalized patients with mild to moderate symptomatic COVID-19, investigators saw 18 cases of severe disease or death in the AZD7442 arm compared to 37 in the placebo cohort.

Related: AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection

It is designed to protect people who do not have a strong enough immune response to vaccines. "These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic," said Hugh Montgomery, the trial's principal investigator.

Other antibody cocktail treatments for COVID-19 have shown varying degrees of success. Regeneron Pharmaceuticals Inc'sREGN therapy showed 72% protection against symptomatic infection in the first week and 93% after that. 

GlaxoSmithKline plc GSKVir Biotechnology Inc's VIR showed a 79% reduction in the risk of hospitalization or death due to any cause. Eli Lilly And Co's LLY therapy showed a 70% reduction in viral load at day seven compared to a placebo.

Price Action: AZN shares are up 0.58% at $60.96 during the market session on Monday's last check.

Photo by Thomas Breher from Pixabay

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralCOVID-19 CoronavirusPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!